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The ability of a heat-inactivated whole virus from a
highly virulent infectious bursal disease virus (hvIBDV)
and VP2 protein from hvIBDV expressed in E. coli provided
protection against a hvIBDV challenge in specific-
pathogen-free (SPF) chickens. Six out of seven chickens
that were injected three times with crude VP2 protein
developed significant antibody titer against IBDV. However,
only four out of the seven chickens survived the hvIBDV
challenge. Despite showing low antibody titer profiles, all
chickens immunized with the heat-inactivated whole virus
also survived the challenged with hvIBDV. However, all of
these chickens had bursal atrophy and mild to moderate
depletion of lymphocytes. Thus, antibodies raised against
IBDV VP2 protein expressed in E. coli and denatured
IBDV proteins induced some degree of protection against
mortality but not against bursal damage following
challenge with hvIBDV.
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Introduction
Infectious bursal disease virus (IBDV) is one of the most
important poultry viruses threatening the chicken industry
worldwide. The immunosuppressive effect of this virus
leads to concurrent secondary infection in the presence of
other viruses or bacteria [18]. The most prominent resulting
lesions are hemorrhage and necrosis of the bursa of Fabricius,
followed by bursal atrophy [20]. The spread of the classical
and variant strains of IBDV has not been fully controlled by
the introduction of attenuated live and killed variant virus
vaccines [18].
Currently, the major problem of IBD is controlling the
highly virulent IBDV (hvIBDV) strains which cause more
severe damage to the bursa and a higher mortality rate. Due
to its markedly different pathogenicity compared to classical
strains [22], it can overcome high levels of maternally
derived antibodies induced by vaccines protective against
previously circulating classical strains of IBDV [31]. The
live intermediate plus vaccines are recommended for farms
where highly virulent strains are found. However, it has
been reported the chickens immunized with intermediate
live vaccines develop a certain degree of bursal atrophy and
immunosuppression [11]. In addition, the commercially
available vaccines have been unable to provide full
protection against a hvIBDV challenge [26].
Infectious bursal disease virus VP2 protein is the major
antigenic component that encodes for at least two epitopes
which induce protective neutralizing antibodies [9]. Hence,
numerous studies have been performed to develop an
alternative IBDV vaccine by expressing the VP2 protein in
various expression systems such as E. coli [3,28],
bacteriophages [6], yeast [25], plant [32], fowlpox virus [4],
herpesvirus [8], adenovirus [10], Semilik Forest virus [23],
baculovirus [30] and plasmid DNA [13]. Vaccination of
chickens with these expression products have resulted in
variable levels of active or passive protection against
mortality and/or bursal damage. However, most of these
studies have focused on the use of a standard classical
challenge (STC) IBDV as challenge virus to test the
recombinant vaccines.
The E. coli expression system is known to be the fastest,
easiest as well as an inexpensive technique for expression of
usable amounts of recombinant protein. Recombinant VP2
expressed in E. coli reacted with a range of monoclonal
antibodies [2,14]. However, it has been reported that VP2
protein expressed in E. coli is not suitable for the production
of subunit vaccine [3,14]. However, a recent study reported
that VP2 protein expressed in E. coli can induce up to 100%
protection against both mortality and bursal damage caused
by STC IBDV [28]. Hence, the efficacy of VP2 protein
expressed in E. coli for protection against virulent IBDV has
not been fully resolved. In addition, the importance of VP2
protein expressed in E. coli for protection against a hvIBDV
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challenge remains unclear. In this study, we studied the
efficacy of heat-inactivated whole virus, of hvIBDV strain
UPM97/61, and its recombinant VP2 protein expressed in
E. coli for protection against a hvIBDV challenge in
specific-pathogen-free (SPF) chickens.
Materials and Methods
Amplification of VP2 gene
The VP2 gene used in this study was obtained from the
local hvIBDV strain UPM97/61 [12]. The amplification,
cloning and sequencing of the VP2 gene was performed
using methods previously described [7]. The putative
complete open reading of the VP2 gene (1351 bp) from
position 132 to 1483 followed the nucleotide numbering
system of Bayliss et al. [5]; it was cloned in the TOPO
cloning vector (Invitrogen, USA) following the methods
recommended by the manufacturer.
Construction of VP2 expression vector
The TOPO cloning vector containing the VP2 gene was
subcloned into a pRSET vector version A (Invitrogen, USA)
using  BglII and EcoRI restriction enzyme sites (MBI
Fermentas, USA). The ligation mixtures were transformed
into competent E. coli BL21-SI. Five clones were picked at
random from LB plates and screened for positive clones as
well as the orientation of the inserted VP2 gene using PCR
methods. The recombinant plasmid was confirmed by
restriction digestion and sequencing of flanking regions.
Analysis of VP2 protein expression
A positive clone was selected for expression in LBON
medium containing 100 µg/ml ampicillin. Expression was
induced by adding sterile NaCl to 0.3 M and incubation was
continued for 5 h before harvesting. The expression of VP2
protein was confirmed by Western blot analysis. Briefly, the
cells were centrifuged at 3500 g for 10 min and the pellet
was resuspended in 1X loading buffer. The mixtures were
subjected to 12% sodium dodecyl sulphate -polyacrylamide
gel electrophoresis (SDS-PAGE) [17] using the vertical slab
gel Mini Protean II (Bio-Rad, USA). The gels were then
stained with Coomasie brilliant blue. For Western blot analysis,
the separated proteins from SDS-PAGE were transferred to
the polyvinylidene difluoride (PVDF) membrane (Immun-
Blot, Bio-Rad, USA). The membranes were incubated with
rabbit IBDV polyclonal anti-sera (1 : 80,000) for 45 min at
room temperature with agitation. The membranes were then
washed in washing buffer and followed by the incubation of
alkaline phosphatase-conjugated antibody to rabbit IgG
(1 : 5000) (KPL, USA). Finally, the blots were developed
with BCIP/NBT color reagents according to manufacturer’s
instructions (KPL, USA).
Optimization, production and purification of the VP2
recombinant protein
Prior to the production of large-scale recombinant protein,
a small scale optimization was carried out to estimate the
optimum conditions for expression. The parameters being
studied were the concentration of NaCl (0.2 M, 0.3 M,
0.4 M), the cell incubation temperature (27
oC, 30
oC, 33
oC)
and the incubation time (1 h, 2 h, 3 h). The production of
large-scale recombinant protein was carried out in one flask
under optimal conditions. The VP2 recombinant protein was
purified from the crude protein using the ProBond Purification
System (Invitrogen, USA) as described by the manufacturer’s
manual. The quantification of the total protein concentration
was determined using Bio-Rad Protein Assay (Bio-Rad,
USA).
Vaccination trial
A total of 43 one-week-old SPF chicks were randomly
allocated to six groups. The first two groups were uninfected
and used as a negative control; the third to sixth groups were
inoculated intramuscularly with 150 µg of crude E. coli
protein, 150 µg of crude VP2 protein, 50 µg of purified VP2
protein and heat-inactivated 10
6 EID50 of UPM97/61 virus.
The inoculums were mixed vigorously with equal amounts
of Freund’s complete adjuvant (Sigma, USA) during the
first immunization while Freund’s incomplete adjuvant
(Sigma, USA) was used for subsequent immunizations.
The immunizations were boosted twice at two week
intervals. Blood for serum was collected from each group at
day 0, 7, 14, 21, 28 and 35 post-immunization. One week
after the last immunization (day 35), all the chickens except
chickens in the second group were challenged orally with
10
4.8 EID50 of UPM97/61 [12]. Chickens in the second group
served as unchallenged negative controls and were used for
scoring bursal lesions. All of the chickens were monitored
daily for mortality, and the bursas were collected for scoring
lesions.
 Scoring bursal lesions
On day eight post-challenge all of the surviving chickens
were sacrificed and the bursa to body weight ratios were
determined. The bursal tissues from both dead and surviving
chickens were also processed for histopathological examination
using a lesion scoring system previously described [12]. The
lesions were defined as: 0 (normal), 1 (mild), 2 (mild to
moderate), 3 (moderate), 4 (moderate to severe) and 5
(severe).
Antibody production assay
An enzyme linked immunosorbent assay (ELISA; IDEXX,
USA) was used to assay the antibody levels produced to
IBDV using the methods recommended by the manufacturer.Immunogenicity of IBDV VP2 protein expressed in  E. coli 243
The antibody titers were calculated based on the following
calculation, log10 titer = 1/09(log10 SP) + 3.36. Samples with
antibody titer greater than log10 2.60, which is equal to 396,
were considered positive.
Results
Expression of VP2 recombinant protein
The pRSET vector expressed the VP2 protein together
with polyhistidine taq at the C-terminus. It was estimated
that the VP2 protein constituted about 3.8% of the total
expressed protein. Based on the Western blot analysis an
expected protein band of VP2 protein was detected with the
approximate size of 50 kDa (Fig. 1). Solubility testing also
indicated that most of the protein was expressed in soluble
form (data not shown).
Optimization of protein expression
Optimal conditions for expression vary depending on the
specific protein being expressed. The main factors affecting
protein expression are the concentration of NaCl, temperature
and the incubation time. Protein expression occurred at
27
oC, 30
oC and 33
oC without a significant difference in the
amount of protein being expressed based on the results of
the Western blot analysis (data not shown).
There was a reduced amount of recombinant protein
produced in 0.1 M NaCl. At 0.2 M to 0.4 M of NaCl, the
amount of protein produced was not significantly different
(Fig. 2). There was no difference at incubation times of 2 h,
3 h and 4 h (data not shown). In general, an incubation
temperature of 30
oC for 3 h and with 0.3 M of NaCl
provided the optimal condition for expression of VP2
protein in the BL21-SI cells.
Induction of antibody responses
The mean IBDV antibody titers for each group were
measured by ELISA from day 0 to 35 days post-immunization
(Table 1). All of the antibody titers were below significant
levels on day 0 indicating that the birds were not infected
with IBDV. The uninfected control birds had no significant
detectable antibody titers throughout the experiment. Six out
of seven chickens that were injected with 150 µg of crude
VP2 protein developed antibody titers against IBDV by day
35 (Table 1 and 2). Compared to the other groups, only
chickens immunized with crude VP2 recombinant protein
had antibody titers more than log10 3.0. As shown in Table 2,
two out of seven chickens in this group had the highest
antibody titers which were log10 3.04 and log10 3.21.
As shown in Table 1, even though the mean antibody
titers at day 21 and 28 were higher than at day 14, the titers
were considered low or negative for IBDV. In order to
confirm that the production of antibodies was not due to the
interference of E. coli proteins present in the cell lysate, a
group of chickens injected with E. coli protein only was
included in the experiment. Results showed that the E. coli
protein did not stimulate the production of antibody above a
significant level (Table 1). None of the chickens had a
Fig. 1. Western blot analysis of VP2 protein. Lane 1, standar d
protein marker; lane 2, BL21-SI host cells only and lane 3, cell
lysate sample of 3 h induced recombinant plasmid. Arrow
indicates the evidence of ~50 kDa VP2 protein detected by rabbi t
polyclonal antibody against IBDV.
Fig. 2. Optimization of NaCl concentration for expression o f
VP2 protein in the E. coli strain BL21-SI. Lane 1, standard
protein marker; lane 2, 0.1 M NaCl; lane 3, 0.2 M NaCl; lane 4,
0.3 M NaCl and lane 5, 0.4 M NaCl. Arrow indicates that the
highest expression of VP2 protein was achieved with 0.3 M
NaCl.244 Abdul Rahman Omar et al.
positive antibody titer prior to challenge by day 35 post
immunization (Table 2). In the case of chickens immunized
with purified VP2 protein, production of antibodies throughout
the study was below significant antibody titers except for
one chicken that was positive for IBDV on day 21 and 28
(Table 1). By day 35 post immunization, two of the chickens
developed a positive antibody titer measuring log 10 2.63 and
log10 2.73 (Table 2). However, chickens immunized with
heat-inactivated UPM97/61 virus had different antibody
titer profiles compared to the other groups. The antibody
titers of two to three chickens in this group were positive for
IBDV at day 14, 21 and 28 (Table 1). By day 35 post
immunization, however, the antibody titers remained low
ranging from log10 2.62 to log10 2.80 (Table 2).
Rate of mortality and protection against hvIBDV
challenge
All of the chickens in the groups that were challenged
with hvIBDV showed signs of inactivity and depression.
Except for the chickens that were immunized with the heat-
inactivated virus, chickens in the other groups began to die
on the third day after being challenged. All of the chickens
immunized with heat-inactivated IBDV survived the
challenge; however, four out of the seven (57%) chickens
that were immunized with 150 µg of crude VP2 protein
remain alive throughout the experiment (Table 1). Only 10
% of the chickens that were not immunized survived the
challenge while two out of seven chickens (28%) survived
the challenge following immunization with E. coli protein.
Post-mortem and histopathological examinations
Post-mortem analysis confirmed that all of the dead chickens
had obvious hvIBDV infection characterized by moderate to
severe bursal edema, hemorrhage and/or necrosis. Even
though all of the chickens immunized with heat-inactivated
virus survived the challenge, they had a reduced bursa to
body weight ratio (Table 3). No observable significant
lesions (score 0) were present in the control birds throughout
the experiment. The majority of chickens that survived the
challenge showed the presence of mild (score 1) and mild to
moderate (score 2) bursal lymphoid depletion (Table 3).
However, histopathological examination of the bursa from
dead chickens showed evidence of moderate to severe
(score 4) and severe (score 5) lymphoid necrosis and
depletion both in the medulla and cortex of the follicles of
the bursal tissues (data not shown). Severe edema with
heavy infiltration of heterophils was also observed in the
interstitial area.
Table 1. Antibody titers, number of chickens with positive antibody titers and percentage of chickens protected against a challenge with
highly virulent IBDV
Group
Titers
 (No. of chickens with positive titers)
 *N o  s u r v i v e d /
No challenged
(% protection) Day 0 Day 7 Day 14 Day 21 Day 28 Day 35
Control 1.63 ± 0.21 (0) 1.49 ± 0.17 (0) 1.67 ± 0.16 (0) 1.66 ± 0.23 (0) 1.75 ± 0.21 (0) 1.85 ± 1.29 (0) 1/10 (10%)
E. coli protein 1.62 ± 0.14 (0) 1.61 ± 0.30 (0) 1.69 ± 0.16 (0) 2.03 ± 0.15 (0) 1.90 ± 0.24 (0) 2.31 ± 0.15 (0) 2/7 (29%)
150 µg crude 
VP2 protein 1.83 ± 0.15 (0) 2.02 ± 0.17 (0) 2.12 ± 0.26 (0) 2.48 ± 0.26 (1) 2.49 ± 0.29 (2) 2.86 ± 0.24 (6) 4/7 (57%)
50 µg purified 
VP2 protein 1.73 ± 0.21 (0) 1.73 ± 0.09 (0) 1.73 ± 0.25 (0) 2.17 ± 0.38 (1) 2.26 ± 0.25 (1) 2.50 ± 0.25 (2) 1/5 (20%)
Heat inactivated
UPM97/61 1.68 ± 0.20 (0) 2.07 ± 0.26 (0) 2.42 ± 0.26 (2) 2.60 ± 0.23 (3) 2.53 ± 0.30 (2) 2.49 ± 0.21 (4) 7/7 (100%)
*The ELISA was carried out using IDEXX Infectious bursal disease antibody test kit at serum dilution of 1 : 500. The antibody tit ers were calculated
based on the following calculation, log 10 titer = 1/09(log10 SP) + 3.36. Samples with antibody titer greater than log 10 2.60 which is equal to 396 were
considered positive. The titers were expressed as mean log 10 ±S D .
Table 2. Antibody titer and outcome of a challenge with highly virulent IBDV
Groups Numbers of
chicken
 Antibody titer prior to challenge at day 35 post 
immunization* Outcome of challenge
 †
Control 10 2.06, 1.97, 1.79, 1.56, 1.48, 1.46, 1.91, 2.19, 2.30, 1.79 D, D, D, D, S, D, D, D, D, D
E.coli protein 7 2.51, 2.50, 2.35, 2.11, 2.26, 2.21, 2.24 D, D, S, D, S, D, D
150 µg crude VP2 protein 7 2.71, 3.21, 3.04, 2.93, 2.98, 2.65, 2.53 D, S, S, S, D, S, D
50 µg purified VP2 protein 5 2.36, 2.38, 2.73, 2.63, 2.39 D, D, S, D, D
Heat inactivated
UPM97/61 7 2.00, 2.80, 2.62, 2.64, 2.54, 2.18, 2.67 S, S, S, S, S, S, S
*The titers were expressed as log 10. Samples with antibody titer greater than log 10 2.60 which is equal to 396 were considered positive.
† D = die, S = survive
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Discussion
The immunogenicity and protective efficacy of non-
replicating IBDV vaccines with heat-inactivated whole
virus and VP2 protein expressed in E. coli were evaluated in
SPF chickens. The VP2 protein was successfully expressed
in soluble form using a pRSET vector following induction
with NaCl in E. coli host cell strain BL21-SI cells.
Compared to uninoculated and E. coli protein inoculated
chickens, chickens inoculated with VP2 protein elicited
specific antibody titers which were detectable by ELISA.
This suggests that the VP2 protein was processed and
presented to the humoral immune system. These results
support previous studies that E. coli expressed VP2 protein
is able to induce the synthesis of antibodies [2,3]. However,
the findings also showed that the antibodies induced by E.
coli expressed VP2 protein reacted specifically with denatured
viral protein, but less well than with intact virus.
There are not many reports on the use of the hvIBDV as a
challenge virus to test recombinant vaccine. It has been only
recently shown that recombinant herpesvirus expressing
VP2 protects chickens against hvIBDV induced illness and
mortality; with 67% of chickens protected against gross
bursal lesions [29]. In another study, it was reported that only
50% of the chickens vaccinated with VP2 DNA vaccine
were protected against mortality but not against bursal
atrophy following challenge with a Korean hvIBDV [15]. In
this study, we demonstrated that chickens immunized three
times with heat-inactivated whole virus and E. coli
expressed VP2 protein developed antibodies against IBDV.
However, only four out of seven chickens, that had the
highest antibody titer after immunized with VP2 protein,
were protected against the hvIBDV challenge. However, all
of the other chickens that had generated a low to moderate
antibody titer, ranging from log10 2.53 to log10 2.71, succumbed
to the hvIBDV challenge.
By contrast, all of the chickens immunized with heat-
inactivated whole virus, despite low antibody titers ranging
from log10 2.00 to log10 2.80, were protected against the
challenge with hvIBDV. The reason for this finding is not
clear; these findings probably represent the presence of
epitopes of other IBDV proteins such as VP3 and/or an
additional VP2 epitope that is not present in the E. coli
expressed VP2 protein; these molecules might have played a
role in inducing protective immunity. It has been shown
earlier that chickens vaccinated with a VP2, VP3 and VP4
based vaccine were better protected against virulent IBDV
compared to chickens vaccinated with VP2 vaccine alone
[15,19]. In addition, it has been predicted that the VP2
protein of a hvIBDV strain HK46 has at least three potential
glycosylation sites [6]. Since, VP2 protein expressed in  E.
coli is poorly glycosylated, some crucial epitopes especially
conformational epitopes, were not formed and presented to
the chicken immune system. Furthermore, it has been
previously shown that induction of neutralizing antibodies
against IBDV infection is dependent on high conformation
of epitopes located on the VP2 protein [9]. Hence, it is likely
that the antibody titer obtained from chickens immunized
with VP2 protein was directed against linear but not
conformational epitopes due to improper folding during the
expression of VP2 in E. coli.
The inability of chickens immunized with purified VP2
protein to confer high antibody titers, associated with
protection against a hvIBDV challenge, is not understood.
The low level of protection may be due to the purification
steps which might have altered or removed the presence of
epitope(s) that are crucial for antibody production.
Alternatively, E. coli expressed VP2 protein may have failed
to form epitopes essential for the induction of neutralizing
antibody; a previous study has shown that chickens immunized
with purified VP2 protein, expressed in baculovirus, were
protected against a STC IBDV challenge [24]. As shown in
Table 1, it appears that the inoculation of E. coli protein
alone does influence the outcome of the challenge study.
The reason for this is unknown; it is likely that E. coli
protein induces the activation of innate immunity. The role
of bacterial proteins, as well as DNA, in stimulating  innate
immunity especially macrophage activity has recently been
reviewed [1,16].
As shown in Table 1, the heat-inactivated UPM97/61
IBDV conferred 100% protection of chickens challenged
with hvIBDV in terms of mortality; this was observed even
Table 3. Bursa to body weight ratio and bursal histopathological scoring of surviving chickens at day 8 post-challenge with highly
virulent IBDV
Groups Bursa over body weight ratio (×10
3) Bursal lymphoid depletion*
Unchallenged control 5.02, 4.41, 4.62, 4.71, 4.56, 4.51, 4.70 0
Unimmunised control 2.22 3+
150 µg crude E.coli protein 2.58, 1.86 2+, 3+
150 µg crude VP2 protein 3.51, 1.55, 1.48, 2.53 1+, 2+, 1+, 1+,
50 µg purified VP2 protein 2.50 2+
Heat-inactivated UPM97/61 1.70, 1.98, 3.64, 1.46, 3.07, 2.36, 1.99 2+, 2+, 1+, 2+, 1+, 1+, 1+
*No observable (score 0) depletion of bursal lymphoid were detected from unchallenged control chickens. However, mild (score +1 ), mild to moderate
(score +2) and moderate (score +3) depletion of lymphocytes were observed from chickens survived the hvIBDV challenge.246 Abdul Rahman Omar et al.
though the average antibody titer was low or below a
significant level. However, it is interesting to note that all of
the chickens that survived the challenge following immunization
with VP2 protein and inactivated whole virus have a
significantly reduced bursa to body weight ratio compared to
the unchallenged chickens. Therefore, this study demonstrated
that the presence of high antibody titers, against the
appropriate conformational epitopes that are present in live
virus, is essential to induce protection against bursal atrophy.
A recent study suggests that the antigen conformation of
IBDV vaccine influences both the quality and quantity of
antibody induced by the VP2 protein [21]. Another
alternative explanation is that the inactivated whole virus
vaccine might have induced other components of the
immune response in particular cell-mediated immune (CMI)
responses. Recently, it has been reported that under normal
conditions, IBDV stimulates a protective antibody response;
however, in the absence of antibody, CMI responses alone
especially T cell responses are adequate for protecting birds
against virulent IBDV [27]. In another recent study, it was
reported that CMI responses, rather than humoral immune
responses, appeared to contribute to the protection of
chickens against hvIBDV infection [15].
In conclusion, the results of this study suggest that
inappropriate expression and folding of IBDV proteins
particularly VP2 protein that occurs in the E. coli expression
system or in heat denatured IBDV proteins, failed to induce
antibody responses that were associated with protection
against hvIBDV induced bursal damage. The protective
efficacy of the studied proteins in inducing protection
against STC IBDV infection is also not known. However,
the humoral antibody responses provided varying degrees of
protection against mortality following a challenge with
hvIBDV. Further studies on the importance of both humoral
antibodies as well as CMI responses following inoculation
with VP2 protein expressed E. coli in inducing protection
against STC IBDV as well as hvIBDV infections are
currently underway.
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